Strumento inattivo

Altre lingue ISIS Pharmaceuticals, Inc. Nasdaq

Azioni

US4643301090

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed	26/06
Ionis Pharmaceuticals' Shares Rise After FDA Accepts Metabolic Disorder Drug Candidate for Priority Review	25/06
Ionis Pharmaceuticals Says FDA Accepts Metabolic Disorder Drug Candidate for Priority Review	25/06
Ionis Pharmaceuticals, Inc. Announces olezarsen FCS New Drug Application Accepted for Priority Review and Enrollment in Phase 3 sHTG Program Completed	25/06
Los resultados del fármaco de Alnylam Pharmaceutical se consideran el "mejor escenario posible" -- Market Talk	24/06
ANALYST RECOMMENDATIONS : Home Depot, Apple, Micron Technology, Anglo American, United Utilities...	21/06
Ionis Pharmaceuticals Insider Sold Shares Worth $644,640, According to a Recent SEC Filing	20/06
Ionis Pharmaceuticals Says Otsuka Obtains Rights for Investigational Hereditary Angioedema Treatment in Asia Pacific	18/06
Ionis to present at TD Cowen Genetic Medicines and RNA Summit	18/06
Ionis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema	18/06
Ionis Pharmaceuticals, Inc. Announces Expand Licensing Agreement with Otsuka Pharmaceutical Co., Ltd	18/06
Ionis to present at TD Cowen Genetic Medicines & RNA Summit	17/06
RECOMENDACIONES DE LOS ANALISTAS UK/EE.UU : Adobe, Bank of America, Boeing, Nvidia, Wise...	14/06
Investors need more time to assess Fed comments	14/06
ANALYST RECOMMENDATIONS : Adobe, Bank of America, Boeing, Nvidia, Wise...	14/06
Ionis Pharmaceuticals : Login Information	06/06
Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema	03/06
Ionis Pharmaceuticals : Donidalorsen Ph3 Data EAACI'24 Webcast Slides	31/05
Ionis Reports 'Positive Results' From Studies of Investigational Treatment for Hereditary Angioedema	31/05
Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema	31/05

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue ISIS Pharmaceuticals, Inc. Nasdaq

Azioni

US4643301090

Altre lingue

Filtri